Bajaj Healthcare Limited — Important, 30-01-2025: General Updates

Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and drug formulation of Pimavanserin, a 34 mg capsule, used for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Globally, Pimavanserin is marketed as NUPLAZID®, which is expected to generate over $1 billion in net sales for 2025.

In a strategic move, the company has extended manufacturing offers for Pimavanserin to various leading Indian pharmaceutical firms, enhancing its domestic market availability. This approval is seen as a significant milestone for Bajaj Healthcare, reinforcing its commitment to growth in the central nervous system (CNS) segment. The company emphasizes its strong manufacturing capabilities, ensuring that both the API and finished product adhere to international quality standards. This expansion is poised to create substantial opportunities and reinforce the company's market presence.